Welcome to Our Reading Room

The HIFU Clinical Literature Reading Room lists dozens of peer-reviewed clinical journal articles related to HIFU surgical ablation.

Visit our Reading Room at www.SonaCareMedical.com/home-clinical-literature for a link to each article.
Sonatherm® Laparoscopic Soft Tissue Ablation System

Renal

Concept Studies


Animal Studies


Human Studies


Review Studies


**Sonablate® 500 Transrectal Prostate HIFU Surgical Ablation System**

**Primary Prostate Cancer – Full Gland HIFU**


1 The Sonablate System is an investigational device, limited by U. S. law to investigational use.

**Primary Prostate Cancer – Partial Gland / Focal Therapy HIFU**


### Recurrent/Salvage Prostate Cancer


**HIFU Technology**

**Feasibility**


**Safety**


**Imaging and Treatment Planning**


**Sonablate System**


**Therapy – Transducers**


**Therapy – Thermal and Cavitation Mechanisms**


**Imaging Technology**


Losa, Andrea et al. “Complications and Quality of Life After Template-assisted Transperineal Prostate Biopsy in Patients Eligible for Focal Therapy.” *Urology* (2013):


Welcome to Our Reading Room

The HIFU Clinical Literature Reading Room lists dozens of peer-reviewed clinical journal articles related to HIFU surgical ablation.

Visit our Reading Room at www.SonaCareMedical.com/home-clinical-literature for a link to each article.
SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, LLC, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500 which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 49 countries outside the U.S., and is pending De Novo submission review by the FDA; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S., has CE Marking, and is approved in more than 30 countries outside the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event the Sonablate® 500 De Novo is granted by the FDA or Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S.